Ipsen Press Releases | Latest News & Updates

Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

– 25 July 2024

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades…

– 25 July 2024

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the…

– 10 June 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…

– 05 June 2024

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary…

– 24 April 2024

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms &…

– 22 April 2024

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

– 02 April 2024

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

– 13 February 2024

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by…

– 08 February 2024

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 200 Press Releases

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Press Release Icon  –  16 September 2024

16 September 2024

Download
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

PARIS, FRANCE, 16 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today final data from the CABINET Phase III trial investigating Cabometyx® (cabozantinib) versus placebo in people living with advanced pancreatic neuroendocrine tumors (pNETs) or advanced extra-pancreatic neuroendocrine tumors…


Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
Press Release Icon  –  15 September 2024

15 September 2024

Download
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

PARIS, FRANCE, 15 September 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today detailed final overall survival (OS) data from the Phase III CONTACT-02 trial investigating the combination of Cabometyx® (cabozantinib) and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC). The…


Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Press Release Icon  –  26 July 2024

26 July 2024

Download
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

PARIS, FRANCE, 26 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today two positive opinions by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for two different rare cholestatic liver disease medicines from the…


Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
Press Release Icon  –  25 July 2024

25 July 2024

Download
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

PARIS, FRANCE, 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024.



Your dedicated contacts

Related links